Venture Partner at Samsara BioCapital · Joined 2023
View Live Interactive Profile →Dan Spiegelman joined Samsara BioCapital as a Venture Partner in 2023 and works with portfolio companies on financial strategy, planning and execution as well as IPO readiness and finance team development. The firm states he has over 30 years of executive finance experience at biotech companies, having served as CFO at BioMarin Pharmaceutical, CFO at CV Therapeutics and Treasurer at Genentech Inc. He currently serves as Board Chairman for Tizona Therapeutics and as Audit Committee Chairman for vTv Therapeutics, Spruce Biosciences and Maze Therapeutics. The firm states he has raised over $5B through financing transactions including IPOs, follow-ons, reverse mergers, convertible debt, bank debt and equity lines of credit, and has both buy side and sell side M&A experience. He co-founded Rapidscan Pharma Solutions, which was sold to GE Healthcare. He received a Bachelor of Arts degree from Stanford University and an M.B.A. from the Stanford Graduate School of Business.